Novo Nordisk A/S vs Workiva Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Workiva Inc trades at $55.02 (market cap $3.21B). The key difference: Novo Nordisk A/S is far larger — about 68.7× Workiva Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| NVO | WK | |
|---|---|---|
Market Cap | $220.53B | $3.21B |
Sector | Health | Technology |
52-Week High | $71.70 | $93.31 |
52-Week Low | $35.29 | $44.31 |
Enterprise Value | $239.49B | $3.14B |
Dividend Yield | 3.63% | — |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →